Kisqali is an oral drug that serves as a first-line treatment for post menopausal women with breast cancer when used in combination with letrozole, another type of breast cancer drug.
The drug slows cancer progression by limiting the over-activation of two proteins that can cause cancer cells to grow and divide too quickly, according to a news release.
More articles on supply chain:
Do PBMs disrupt patient-physician relationships? 6 thoughts
Which news channel covers high drug costs the most?
6 things keeping supply chain leaders up at night
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
